SPK-HD-77 is a potent Helicobacter pylori growth inhibitor, shown to exhibit sub-micromolar range of growth inhibition of the bacteria. Drug metabolism and pharmacokinetics (DMPK) studies conducted on SPK-HD-77 reveal the molecule as a potent pre-clinical candidate for anti-H. pylori therapy.
Purity: > 97% (HPLC)
Biological activity:
1. SPK-HD-77 is a potent Helicobacter pylori growth inhibitor, with a minimum inhibitory concentration (MIC) of 0.804 µg/mL on the H. pylori strains ATCC 26695 and I10. 2. SPK-HD-77 is a good pre-clinical candidate (lead) with high plasma protein binding, moderate MLM stability, no CYP inhibition, and better bioavailability. 3. Further, stomach tissue analysis shows that compound availability is good in the stomach than in plasma.*